[{"id":"037526fa-c1e8-4a48-8938-114bba08f003","acronym":"CC-95251-ST-001","url":"https://clinicaltrials.gov/study/NCT03783403","created_at":"2021-07-05T17:19:06.404Z","updated_at":"2024-07-02T16:35:27.351Z","phase":"Phase 1","brief_title":"A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers","source_id_and_acronym":"NCT03783403 - CC-95251-ST-001","lead_sponsor":"Celgene","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Rituxan (rituximab) • anzurstobart (BMS-986351)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 02/01/2019","start_date":" 02/01/2019","primary_txt":" Primary completion: 06/20/2024","primary_completion_date":" 06/20/2024","study_txt":" Completion: 08/23/2024","study_completion_date":" 08/23/2024","last_update_posted":"2023-12-01"}]